Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030,
according to a new report by Grand View Research, Inc. As these less invasive
biopsies are able to address a number of significant challenges associated with
conventional biopsies such as, high level of invasiveness, incompleteness of
cancer information that is acquired, associated post-biopsy serious medical
complications, and subsequent cost inclusions. A growing need for more
advanced, efficient and accurate method which provides a holistic view of the
tumor and metastasis is the prime factor fueling rapid development of liquid
biopsies.
The market has gained considerable traction in the past
couple of years. A number of clinical research projects related to circulating
tumor cells, and cell-free tumor DNA have been initiated in the latter half of
the past decade. As a result, there are a number of ongoing clinical trials
that are due to be completed between post 2017-18. It is expected that upon
successful completion, commercialization of these assays and tests will provide
the market a significant boost in potential addressable target revenue and fuel
growth through to 2030.
Browse
full report by Grand View Research :
Further key findings from the report suggest:
·
In terms of applications, therapy selection
of metastatic cancers is the key area of liquid biopsy usage as these provide
significant insights into the unique genetic information encoded in CTCs and
ctDNAs. Furthermore, with the addition of more research data reinforcing the
usage of liquid biopsies over the coming years, it is expected that their
application for molecular monitoring of diseases will also be a lucrative
source of revenue through to 2030
·
Key biomarkers that any liquid biopsy
targets include circulating tumor cells, circulating tumor DNA and exosomes
that are macrovesicles containing tumor RNA, or tumor protein freely
circulating in the patient’s bloodstream. Assays for ctDNA are expected to
account for the largest share of revenue through to 2030 owing to the currently
present assays and expected number of products that are to be commercialized
over the coming decade.
·
Development of parallel multi-gene analysis
using next generation sequencing technology is the underlying factor that has
enabled oncologists to more efficiently sequence ctDNA and gain insights
related to cancer metastasis and the related mechanism. This understanding
provides a patient-centric systemic view of cancer and aids in its long term
monitoring.
·
North America, specifically the U.S.
accounts for the largest share of revenue for the development of liquid biopsy
market. The region was observed to account for around 50% of the global
potential in 2015 owing to the high number clinical development projects
underway for the commercialization of CTC and ctDNA assays till 2020.
Furthermore, throughout the forecast period, U.S. is expected to dominate
revenue generation owing to the dynamic nature & being the region of prime
activity, research and development with respect to liquid biopsy and next
generation sequencing technology.
·
Although, post successful commercialization
through to 2030, Asia Pacific is expected to be a lucrative region for
development as it is expected to be characterized by the presence of a large
patient population base, developing healthcare framework and growth in
integration of more advanced healthcare practices.
·
The market is in its developing phase and
is characterized by the presence of a number of relatively smaller entities
involved in innovation and new product development. Companies such as Biocept,
Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen,
Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene
are operating in the space and have a number of commercialized assays in their
portfolios for liquid biopsy.
·
Furthermore, as this space has a high
lucrative potential, and is considerably influenced by the developments in NGS
technology, there are a number of major players that have ongoing
investigational & observational clinical trials and are due to be completed
by 2017 to 2019. Collectively, over 30 clinical trials are currently registered
as active by companies including Illumina, Foundation Medicine, Natera Inc.,
Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S.
alone. Anticipated successful commercialization of these products is expected
to fuel growth over the forecast period.
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has
segmented the liquid biopsy market on the basis of application, sample type,
biomarker, technology, and region:
Global
Liquid Biopsy Outlook, by Application (Revenue, USD Million, 2013 - 2030)
·
Therapy Selection for Metastatic Breast
Cancer (MBS)
·
Therapy Selection for Other Metastatic
Cancer
·
Molecular Health Monitoring
Global Liquid
Biopsy, by Sample Type (Revenue, USD Million, 2013 - 2030)
·
Blood Sample based
·
Urine Sample based
·
Other Bio Fluids (Tissue fluids and Saliva)
based
Global
Liquid Biopsy Outlook, by Biomarker, (Revenue, USD Million, 2013 - 2030)
·
Circulating Tumor Cells (CTC)
·
Circulating Tumor DNA (ctDNA)
·
Exosomes
Global
Liquid Biopsy Outlook, by Biomarker, (Revenue, USD Million, 2013 - 2030)
·
Multi - gene - parallel Analysis (NGS)
·
Single Gene Analysis (PCR Microarrays)
Global
Liquid Biopsy Market, Regional Outlook (Revenue, USD Million, 2013 - 2030)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o South
Africa
Access
press release by Grand View Research: http://www.grandviewresearch.com/press-release/liquid-biopsy-market
About
Grand View Research
Grand View Research, Inc. is a U.S. based
market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment